{
    "Trade/Device Name(s)": [
        "Capture-CMV",
        "Capture-CMV\u00ae"
    ],
    "Submitter Information": "Immucor, Inc.",
    "510(k) Number": "K203612",
    "Predicate Device Reference 510(k) Number(s)": [
        "K183571"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LJO"
    ],
    "Summary Letter Date": "September 16, 2020",
    "Summary Letter Received Date": "December 10, 2020",
    "Submission Date": "March 16, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.3175"
    ],
    "Regulation Name(s)": [
        "Cytomegalovirus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "immunology"
    ],
    "Analyte(s)": [
        "Cytomegalovirus antibodies (IgG, IgM)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NEO Iris",
        "Galileo NEO"
    ],
    "Method(s)/Technology(ies)": [
        "Solid phase red cell adherence"
    ],
    "Methodologies": [
        "Antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Immucor Capture-CMV solid phase red cell adherence assay for CMV antibody detection using NEO Iris and upgraded Galileo NEO instruments",
    "Indications for Use Summary": "Qualitative in vitro test system for detecting IgG and IgM antibodies to cytomegalovirus in human serum or plasma, intended for screening patients for evidence of previous CMV infection with manual, semi-automated, NEO Iris, or Galileo NEO methods",
    "fda_folder": "Microbiology"
}